Accueil
Détail de l'auteur
Documents disponibles écrits par cet auteur
Ajouter le résultat dans votre panier Faire une suggestion Affiner la rechercheArticle : Périodique
J. REHM ; M. X. REHM ; H. ALHO ; A. ALLAMANI ; H. J. AUBIN ; G. BÜHRINGER ; J. B. DAEPPEN ; U. FRICK ; A. GUAL ; N. HEATHER |Aim: To describe guidelines and common practices for alcohol dependence treatment in Europe. Design: Systematic and qualitative review; for each country, guidelines were identified via systematic literature research, followed by interviews with[...]Périodique
M. AALTO ; SEPPÄ K. ; P. MATTILA ; MUSTONEN H. ; RUUTH K. ; HYVÄRINEN H. ; PULKKINEN H. ; H. ALHO ; SILLANAUKEE P. | 2001ENGLISH : The aim of this research was to evaluate the effectiveness of long- term brief intervention in routine general practice. In five primary care out-patient clinics in a Finnish town, 296 male early-phase heavy drinkers consulting a gen[...]Article : Périodique
E. LAUNONEN ; H. ALHO ; E. KOTOVIRTA ; I. WALLACE ; K. SIMOJOKI |Background: Diversion (i.e. selling or giving away) of opioid maintenance treatment (OMT) medications is a challenge that concerns many units providing OMT worldwide and tools for prevention are needed. The object of this study was to examine th[...]Périodique
RAPELI P. ; FABRITIUS C. ; H. ALHO ; SALASPURO M. ; WAHLBECK K. ; KALSKA H. | 2007ENGLISH : BACKGROUND: Both methadone- and buprenorphine-treated opioid-dependent patients frequently show cognitive deficits in attention, working memory, and verbal memory. However, no study has compared these patient groups with each other d[...]Article : Périodique
Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus
M. DEMATTEIS ; M. AURIACOMBE ; O. D'AGNONE ; L. SOMAINI ; N. SZERMAN ; R. LITTLEWOOD ; F. ALAM ; H. ALHO ; A. BENYAMINA ; J. BOBES ; J. P. DAULOUEDE ; C. LEONARDI ; I. MAREMMANI ; M. TORRENS ; S. WALCHER ; M. SOYKA |Introduction: Management of patients with opioid use disorder (OUD) commonly includes opioid agonist therapy (OAT) as a part of an integrated treatment plan. These interventions are associated with proven benefits to the individual and society. [...]Article : Périodique
J. GREBELY ; J. BRUNEAU ; J. V. LAZARUS ; O. DALGARD ; P. BRUGGMANN ; C. TRELOAR ; M. HICKMAN ; M. HELLARD ; T. ROBERTS ; L. CROOKS ; H. MIDGARD ; S. LARNEY ; L. DEGENHARDT ; H. ALHO ; J. BYRNE ; J. F. DILLON ; J. J. FELD ; G. FOSTER ; D. GOLDBERG ; A. R. LLOYD ; J. REIMER ; G. ROBAEYS ; M. TORRENS ; N. WRIGHT ; I. MAREMMANI ; B. L. NORTON ; A. H. LITWIN ; G. J. DORE ; International Network on Hepatitis in Substance Users |Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among th[...]Nouveauté
Article : Périodique
SIMOJOKI K. ; H. VORMA ; H. ALHO |BACKGROUND: In Finland, buprenorphine (Subutex) is the most abused opioid. In order to curb this problem, many treatment centres transferred (forced transfer) their buprenorphine patients to the buprenorphine plus naloxone (Suboxone) combination[...]
